ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

ClinicalTrials.gov ID: NCT03273153

Public ClinicalTrials.gov record NCT03273153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Study identification

NCT ID
NCT03273153
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
446 participants

Conditions and interventions

Interventions

  • Atezolizumab Drug
  • Cobimetinib Drug
  • Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2017
Primary completion
Apr 14, 2019
Completion
Feb 18, 2021
Last update posted
Sep 20, 2022

2017 – 2021

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
University of Arizona Cancer Center Tucson Arizona 85719
City of Hope Comprehensive Cancer Center Duarte California 91010
USC Norris Cancer Center Los Angeles California 90033
USC Norris Cancer Center; USC Oncology Hematology Newport Beach Newport Beach California 92663
University of California at Irvine Medical Center; Department of Oncology Orange California 92868
Stanford Comprehensive Cancer Center Stanford California 94305
UF Health Cancer Center at Orlando Health Orlando Florida 32824
Florida Cancer Specialist, North Region St. Petersburg Florida 33705
Moffitt Cancer Center Tampa Florida 33612
Florida Cancer Specialists West Palm Beach Florida 33401
Northwestern University Chicago Illinois 60611
Massachusetts General Hospital;Hematology/ Oncology Boston Massachusetts 02114
University of Michigan; Michigan Institute for Clinical and Health Research (MICHR) Ann Arbor Michigan 48109
Dartmouth-Hitchcock Medical Center; Hematology/Oncology Lebanon New Hampshire 03756
Morristown Medical Center Morristown New Jersey 07962
Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists Winston-Salem North Carolina 27103
TriHealth Hatton Institute; Surgical Education Cincinnati Ohio 45220
St. Luke's University Health network Bethlehem Pennsylvania 18015
Thomas Jefferson University Hospital;Medical Oncology Philadelphia Pennsylvania 19107
SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee 37404
Sarah Cannon Research Institute Nashville Tennessee 37203
M.D Anderson Cancer Center; Uni of Texas At Houston Houston Texas 77030
West Virginia University Hospitals Inc Morgantown West Virginia 26056

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03273153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2022 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03273153 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →